Please login to the form below

Not currently logged in
Email:
Password:

balugrastim

This page shows the latest balugrastim news and features for those working in and with pharma, biotech and healthcare.

EMA backs 15 new medicines for use in EU

EMA backs 15 new medicines for use in EU

tilmanocept) for the delineation and localisation of sentinel lymph nodes; and Teva's Egranli (balugrastim) to treat chemotherapy-induced neutropenia.

Latest news

  • Teva withdraws US filing for cancer biologic Teva withdraws US filing for cancer biologic

    FDA requests more data for balugrastim. Teva said this week it is "assessing its options" after withdrawing the US drug filing for long-acting white cell stimulator balugrastim. ... The FDA has agreed to work with Teva in designing any additional studies

  • Neulasta rival from Teva cleared in EU Neulasta rival from Teva cleared in EU

    Teva's biologics pipeline also includes reslizumab, a monoclonal antibody targeting interleukin-5 (IL-5) in phase III for moderate-to-severe asthma, and an albumin-fused G-CSF called balugrastim

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

David Atkins
A snapshot of Congenica
PME talks to CEO David Atkins...
Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...

Infographics